Objective: To investigate the clinical effects of alprostadil on diabetic nephropathy and its influence on serum inflammatory factors and renal fibrosis indexes. Methods: 120 patients with diabetic nephropathy treated in our hospital from June 2015 to June 2016 were selected. They were divided into alprostadil group and conventional group (60 cases in each group) according to odd-even numbers for visiting. The patients in the two groups were both treated with conventional therapy and the patients in the alprostadil group took alprostadil at the same time. The treatment effects of the two groups were compared. Results: The levels of fasting blood glucose, SBP and DBP in the two groups before and after treatment were compared, the differences were not statistically significant (P>0.05). Blood urea nitrogen, serum creatinine (Scr), urinary albumin (UAER) and β2-microglobulin (β2-MG) levels of the two groups before treatment were not statistically significant(P>0.05);Scr, UAER and β2-MG levels in alprostadil group were all lower than those in conventionalgroup after treatment (P<0.05); Before treatment, the differences of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels of the two groups were not statistically significant (P>0.05); After treatment, IL-6, TNF-α levels in alprostadil group were both lower than those in conventional group (P<0.05); Before treatment, laminin (LN), procollagen Ⅲ (PC Ⅲ), collagen Ⅳ(CⅣ) levels were not statistically significant(P>0.05); After treatment, plasma LN, PCⅢ and CⅣ levels in alprostadil group were all lower than those in conventional group (P<0.05). Conclusion: Alprostadil can significantly improve renal function, reduce the levels of serum inflammatory factors and renal fibrosis indexes in patients with diabetic nephropathy. |
[1] 王珊珊,常宝成,单春艳,等.前列地尔序贯疗法治疗老年临床糖尿病肾病期患者的疗效观察[J].中华老年医学杂志,2014,33(2):154-158.
[2] 卞丽丽,尚文斌.缬沙坦联合前列地尔治疗糖尿病肾病的meta分析[J].中华内分泌代谢杂志,2015,31(5):408-412.
[3] 金洁娜,孙慧艳,徐赵钕,等.前列地尔治疗早期糖尿病肾病疗效及安全性观察[J].重庆医学,2016,45(10):1337-1338.
[4] LUO C,LI T,ZHANG C,et al.Therapeutic effect of alprostadil in diabetic nephropathy:possible roles of angiopoietin-2 and IL-18[J].Cellular Physiology & Biochemistry International Journal of Experimental Cellular Physiology Biochemistry & Pharmacology,2014,34(3):916-928.
[5] 李香,王丽宏,傅雪莲,等.microRNA在糖尿病肾病中的作用[J].东南大学学报:医学版,2015,34(2):325-328.
[6] 何玉明,丁宪群.尿毒清颗粒对早中期糖尿病肾病患者炎症因子影响的临床研究[J].中药药理与临床,2015,18(6):160-162.
[7] 王健,张凤平.前列地尔用于糖尿病肾病患者效果观察[J].山东医药,2015,15(36):107-108.
[8] 马亚丽,陈芳,时军,等.缬沙坦联合前列地尔对早期糖尿病肾病的临床研究[J].中国临床药理学杂志,2016,32(5):409-411.
[9] LIU G,SHEN Y,YOU L,et al.Tripterygium wilfordii polyglycoside suppresses inflammatory cytokine expression in rats with diabetic nephropathy[J].Chinese Journal of Cellular and Molecular Immunology,2014,30(7):721-724.
[10] 韩吉祥.薄芝糖肽、前列地尔联合益气养阴通络方对早期糖尿病肾病疗效观察[J].中药药理与临床,2015,10(2):191-192.
[11] 祁佳,唐跃年,张宇锋,等.肾康注射液联合前列地尔治疗糖尿病肾病的临床效果系统评价[J].山东医药,2015,15(25):12-15.
[12] 任传永,肖正武,张青森,等.前列地尔联合坎地沙坦对糖尿病肾病患者血清瘦素的影响[J].中国新药与临床杂志,2015,14(1):32-35.
[13] VASILOPOULOU E,KOLATSI-JOANNOU M,LINDENMEYER M T,et al.Loss of endogenous thymosin 4 accelerates glomerular disease[J].Kidney International,2016,90(5):1056-1070.
[14] 钟思干,杨飞,陈爱文,等.前列地尔对合并糖尿病的冠心病患者介入治疗中造影剂肾病的预防作用研究[J].中国全科医学,2014,17(31):3720-3723.
[15] 洪兵,陈丽娟,殷学超,等.中药足浴结合前列地尔注射对糖尿病周围神经病变的疗效观察及对血清脂联素、IL-6及TNF-α水平的影响[J].中华中医药学刊,2015,33(12):2891-2894. |
